Skip to main content
main-content

Spondyloarthropathies

Clinical trials

24-07-2018 | Psoriatic arthritis | Article

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2

Genovese MC et al. Rheumatology (Oxford) 2018: key182. doi: 10.1093/rheumatology/key182

25-06-2018 | Psoriatic arthritis | Article

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Gottlieb AB et al. Rheumatology (Oxford) 2018: key161. doi: 10.1093/rheumatology/key161

29-06-2018 | Adalimumab biosimilar | Article

Similar pharmacokinetics of the adalimumab (Humira®) biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, randomized, open-label, parallel-group trials

The authors present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of adalimumab biosimilar BI 695501 delivered via autoinjector versus prefilled syringe.

Ramael S et al. Rheumatol Ther 2018. doi: 10.1007/s40744-018-0119-1

Similar pharmacokinetics of the adalimumab (Humira®) biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, randomized, open-label, parallel-group trials

The authors present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of adalimumab biosimilar BI 695501 delivered via autoinjector versus prefilled syringe [read more].
Ramael S et al. Rheumatol Ther 2018. doi: 10.1007/s40744-018-0119-1

07-06-2018 | Psoriatic arthritis | Article

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: Results from the FUTURE 2 study

McInnes IB et al. Arthritis Res Ther 2018; 20: 113. doi: 10.1186/s13075-018-1610-3

04-04-2018 | Psoriatic arthritis | Article

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: Results of the randomized, placebo-controlled PALACE 4 trial

Wells AF et al. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key032

17-03-2018 | Secukinumab | Article

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomized, double-blind, phase III FUTURE 5 study

Mease P et al. Ann Rheum Dis 2018; Advance online publication. doi: 10.1136/annrheumdis-2017-212687

07-07-2017 | Psoriatic arthritis | Article

Elderly psoriatic arthritis patients on TNF-α blockers: Results of an Italian multicenter study on minimal disease activity and drug discontinuation rate

The results of this study suggest that tumor necrosis factor-alpha blockers are effective and safe in elderly patients with psoriatic arthritis and age should not be considered a limitation to their use.

Costa L, Lubrano E, Ramonda R et al. Clin Rheumatol 2017;36:1797–1802. doi:10.1007/s10067-017-3697-3

08-08-2017 | Psoriatic arthritis | Article

Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis

This meta-analysis finds that apremilast, secukinumab, and ustekinumab are all more efficacious than placebo; however, there are no significant differences in the efficacy and safety between the drugs.

Song GG, Lee YH. Z Rheumatol 2017. doi:10.1007/s00393-017-0355-8

07-03-2017 | Psoriatic arthritis | Article

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

Harrold et al. perform a retrospective analysis of observational data collected on patients with psoriatic arthritis to further understanding of the factors associated with therapy persistence in patients.

Harrold LR et al. Clin Rheumatol 2017;36:895–901. doi:10.1007/s10067-017-3593-x

24-08-2016 | Axial spondyloarthritis | Article

Web-based physiotherapy for people with axial spondyloarthritis (WEBPASS) – a study protocol

Introducing a study to assess adherence to a 12-month individualized web-based physiotherapy program for people with axial spondyloarthritis. 

Paul L et al. BMC Musculoskelet Disord 2016;17:360. doi:10.1186/s12891-016-1218-1

19-01-2016 | Ankylosing spondylitis | Article

Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case–control study based on national registers

Results from this study point to environmental factors as predictors of ankylosing spondylitis; factors related to childhood exposure may also be of importance in the disease pathogenesis.

Lindström U et al. Arthritis Res Ther 2016;18:16. doi:10.1186/s13075-016-0917-1

09-08-2015 | Ankylosing spondylitis | Article

Decreased physical activity and cardiorespiratory fitness in adults with ankylosing spondylitis: a cross-sectional controlled study

Study from O’Dwyer et al shows that adults with ankylosing spondylitis (AS) participated in less physical activity (PA) than population controls despite exercise being a key component of AS management.

O’Dwyer T, O’Shea F, & Wilson F. Rheumatol Int 2015;35:1863–1872. doi:10.1007/s00296-015-3339-5

Image Credits